Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

IJTLD open

Showing results (191-200 of 296) with videos related to

Pageof 30
Sort By:
IJTLD Open|July 11, 2024
Characteristics of and treatment outcomes in rifampicin-intolerant patientsR Mangat, S K Brode, H K Mah, et al.
IJTLD Open|July 11, 2024
A pilot cross-sectional study of non-communicable diseases in TB household contactsY Hamada, A Lugendo, T Ntshiqa, et al.
IJTLD Open|July 18, 2024
Prevalence, incidence and determinants of QuantiFERON<sup>TM</sup> positivity in South African schoolchildrenJ Stewart, N Walker, K Jennings, et al.
IJTLD Open|July 18, 2024
Determinant of catastrophic costs associated with treatment for rifampicin-resistant TB in households in the Republic of MoldovaA Ciobanu, V Plesca, S Doltu, et al.
IJTLD Open|July 5, 2024
Health system costs of providing outpatient care for diabetes in people with TB in the PhilippinesT Yamanaka, M C Castro, J P Ferrer, et al.
IJTLD Open|July 5, 2024
Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in UgandaA Musinguzi, H E Aschmann, J L Kadota, et al.
IJTLD Open|June 26, 2024
Key drivers of the TB epidemic in Suriname and priority actions to reduce incidence and mortalityE Commiesie, D Stijnberg, J van den Boogaard, et al.
IJTLD Open|June 26, 2024
Clinical spectrum of disease and outcomes in children with Omicron SARS-COV-2 infection in Cape Town, South AfricaC Bekker, I Dewandel, A Redfern, et al.
IJTLD Open|July 5, 2024
Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European RegionG B Migliori, O Korotych, J Achar, et al.
IJTLD Open|July 22, 2024
Prevalence and predictors of NTM in presumed/confirmed drug-resistant TBE T Abbew, R Laryea, F Sorvor, et al.
Pageof 30

Showing results (191-200 of 296) with videos related to

Sort By:
Pageof 30
IJTLD Open|July 11, 2024
Characteristics of and treatment outcomes in rifampicin-intolerant patientsR Mangat, S K Brode, H K Mah, et al.
IJTLD Open|July 11, 2024
A pilot cross-sectional study of non-communicable diseases in TB household contactsY Hamada, A Lugendo, T Ntshiqa, et al.
IJTLD Open|July 18, 2024
Prevalence, incidence and determinants of QuantiFERON<sup>TM</sup> positivity in South African schoolchildrenJ Stewart, N Walker, K Jennings, et al.
IJTLD Open|July 18, 2024
Determinant of catastrophic costs associated with treatment for rifampicin-resistant TB in households in the Republic of MoldovaA Ciobanu, V Plesca, S Doltu, et al.
IJTLD Open|July 5, 2024
Health system costs of providing outpatient care for diabetes in people with TB in the PhilippinesT Yamanaka, M C Castro, J P Ferrer, et al.
IJTLD Open|July 5, 2024
Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in UgandaA Musinguzi, H E Aschmann, J L Kadota, et al.
IJTLD Open|June 26, 2024
Key drivers of the TB epidemic in Suriname and priority actions to reduce incidence and mortalityE Commiesie, D Stijnberg, J van den Boogaard, et al.
IJTLD Open|June 26, 2024
Clinical spectrum of disease and outcomes in children with Omicron SARS-COV-2 infection in Cape Town, South AfricaC Bekker, I Dewandel, A Redfern, et al.
IJTLD Open|July 5, 2024
Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European RegionG B Migliori, O Korotych, J Achar, et al.
IJTLD Open|July 22, 2024
Prevalence and predictors of NTM in presumed/confirmed drug-resistant TBE T Abbew, R Laryea, F Sorvor, et al.
Pageof 30